Psychedelic Trials

Psilocybin-assisted Psychotherapy for Treatment of Alcohol Use Disorder
This pilot study will collect preliminary data that measures the effects of psychedelic-assisted psychotherapy on patients struggling with alcohol use.
Status: Not yet recruiting
Start date: 2022-08-01
Phase II
Open
20 participants
Interventional
Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder
The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD).
Status: Not yet recruiting
Start date: 2022-10-10
Phase II
Blinded
90 participants
Interventional
A Dose-Finding Study of MM-120 for the Treatment of Anxiety Symptoms
This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).
Status: Recruiting
Start date: 2022-06-27
Phase II
Blinded
200 participants
Interventional
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC)
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
Status: Not yet recruiting
Start date: 2022-10-01
Blinded
100 participants
Interventional
Psilocybin Therapy in Advanced Cancer
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose psilocybin 1mg) in the treatment of anxiety, depression, and existential distress in advanced cancer.
Status: Not yet recruiting
Start date: 2022-11-01
Phase II
Blinded
300 participants
Interventional
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
Status: Not yet recruiting
Start date: 2022-09-01
Phase II
Open
10 participants
Interventional
Microdosing Psilocybin for Depression
This double-blind randomized-controlled trial will assess the effects of two small doses of synthetic psilocybin in capsule form each week for six weeks in people with depression.
Status: Planned
Start date: 2022-11-01
Phase II
Blinded
266 participants
Interventional
KRN-101 for Cancer-Related Distress
This study will investigate the effects of KR-101 (a psilocybin-based medicine) in participants with cancer-related distress.
Status: Planned
Phase II
Open
Interventional
Safety and efficacy of psilocybin-assisted psychotherapy for Generalised Anxiety Disorder [Psi-GAD-1]: a randomised triple-blind active-placebo-controlled trial
In this study, we will complete a randomised controlled trial to test a 7 week (2 dose) psilocybin-assisted psychotherapy for the treatment of GAD. 72 individuals will be randomly assigned to receive two doses either psilocybin (25mg or 30mg, oral) or placebo (diphenhydramine, 75mg or 100mg, oral) with three weeks between doses.
Status: Recruiting
Start date: 2022-01-10
Phase II
Blinded
70 participants
Interventional
A Study of a Psilocybin Analog (CYB003) in Participants With Major Depressive Disorder
A Study of a Psilocybin Analog (CYB003) in Participants With Major Depressive Disorder
Status: Not yet recruiting
Start date: 2022-07-19
Phase I
Blinded
40 participants
Interventional
MM-120 in Treatment of Generalized Anxiety Disorder (MMED008)
The primary objective of the study is to determine the reduction in anxiety symptoms for up to twelve weeks after a single administration of MM-120, compared across five treatment arms.
Status: Planned
Phase II
Blinded
200 participants
Interventional
Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function (MASM)
To study the effects of MDMA, compared to a prototypical stimulant, on social motivation, social ability, and neural indices of social function in healthy volunteers.
Status: Recruiting
Start date: 2022-05-01
Phase I
Blinded
36 participants
Interventional
Psilocybin Versus Ketamine in Treatment-Resistant Depression (PSIKET_001)
e main goal is to compare the antidepressant effects of psilocybin and ketamine in patients with TRD versus the antidepressant inactive substance midazolam.
Status: Recruiting
Start date: 2021-05-01
Phase II
Open
60 participants
Interventional
Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT DR)
The present study is a modern randomized cross-over trial, investigating different continuous intravenous DMT dose rates over a broad dose range.
Status: Not yet recruiting
Start date: 2022-09-01
Phase I
Blinded
24 participants
Interventional
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
This open-label fMRI study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with treatment-resistant major depressive disorder.
Status: Not yet recruiting
Start date: 2022-06-01
Phase II
Open
20 participants
Interventional
Effects of Repeated Psilocybin Dosing in OCD
This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD.
Status: Not yet recruiting
Start date: 2022-11-01
Phase I
Blinded
30 participants
Interventional
Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache (LCH)
LSD has been reported to abort attacks, decrease the frequency and intensity of attacks, and induce remission in patients suffering from cluster headaches (CH).
Status: Recruiting
Start date: 2019-01-02
Phase II
Blinded
30 participants
Interventional
COMP360 psilocybin in autistic adults
The double-blind, randomised, placebo-controlled study (“PSILAUT”) will investigate whether there is a difference in the function of serotonin brain networks in autistic and non-autistic adults.
Status: Planned
Phase II
Blinded
70 participants
Interventional
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia.
Status: Completed
Start date: 2021-04-26
Phase II
Open
37 participants
Interventional
A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders (MED1)
This Phase II trial with 18 participants will investigate the safety and feasibility of using MDMA-AT for eating disorders (anorexia nervosa & binge eating disorder).
Status: Not yet recruiting
Start date: 2020-07-01
Phase II
Open
12 participants
Interventional
Single Ascending Dose Study With BPL-003 in Healthy Subjects
The study will evaluate the safety, tolerability and PK profile of BPL-003 (5-MeO-DMT) in healthy subjects.
Status: Recruiting
Start date: 2022-02-14
Phase I
Blinded
56 participants
Interventional
An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder
The primary objective is to evaluate the effect of MDMA-assisted psychotherapy for MDD in clinician-rated depression scores, as measured by the mean change in MADRS scores from Visit 4 (Baseline) to Visit 13 (approximately 12 weeks post Baseline).
Status: Recruiting
Phase II
Open
12 participants
Interventional
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
The purpose of this research study is to investigate the safety and feasibility of two oral doses of psilocybin when combined with behavioural support for methamphetamine use disorder (MUD).
Status: Planned
Start date: 2022-04-18
Phase I
Open
12 participants
Interventional
Comparing the Effects of Psilocin and Psilocybin in Healthy Adults
To compare the physiological and psychological effects of psilocin taken orally by pill or sublingually by dissolving a tablet under the tongue to those of psilocybin taken by pill in healthy adults.
Status: Recruiting
Start date: 2022-07-04
Phase I
Blinded
20 participants
Interventional
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
The safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).
Status: Recruiting
Start date: 2022-04-11
Phase II
Open
29 participants
Interventional
Effects of Psilocybin in Post-Treatment Lyme Disease
This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).
Status: Not yet recruiting
Start date: 2022-04-18
Phase I
Open
20 participants
Interventional
Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder
To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 (psilocybin) among individuals with Binge Eating Disorder.
Status: Not yet recruiting
Start date: 2022-10-03
Open
10 participants
Interventional
Acute Effects of R- and S-MDMA in Healthy Subjects (R-S-MDMA)
The present study compares acute responses to R-MDMA, S-MDMA, MDMA, and placebo in a cross-over study in healthy subjects.
Status: Not yet recruiting
Start date: 2022-06-30
Phase I
Blinded
24 participants
Interventional
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain
The long-term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment.
Status: Not yet recruiting
Start date: 2022-05-01
Phase I
Blinded
80 participants
Interventional
Microdosing Psychedelics to Improve Mood
The purpose of this trial is to examine the safety and efficacy of small (2mg) sub hallucinogenic doses of psilocybin in people with Persistent Depressive Disorder.
Status: Not yet recruiting
Start date: 2022-04-04
Phase II
Blinded
50 participants
Interventional

Find Psychedelic Trials

Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.

The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account